S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:IRIXIRIDEX Stock Price, Forecast & News

$2.37
-0.14 (-5.58 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.34
Now: $2.37
$2.63
50-Day Range
$1.95
MA: $2.12
$2.51
52-Week Range
$1.22
Now: $2.37
$4.24
Volume30,200 shs
Average Volume43,010 shs
Market Capitalization$32.68 million
P/E RatioN/A
Dividend YieldN/A
Beta1.12
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. It also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures. In addition, the company offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system that delivers laser to treat glaucoma; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe Illuminate and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products used in vitrectomy procedures. It serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. IRIDEX Corporation markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was founded in 1989 and is headquartered in Mountain View, California.
Read More
IRIDEX logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.93 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
Current SymbolNASDAQ:IRIX
CUSIPN/A
Phone650-940-4700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$43.45 million
Book Value$1.65 per share

Profitability

Net Income$-8,810,000.00

Miscellaneous

EmployeesN/A
Market Cap$32.68 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
$2.37
-0.14 (-5.58 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IRIX News and Ratings via Email

Sign-up to receive the latest news and ratings for IRIX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











IRIDEX (NASDAQ:IRIX) Frequently Asked Questions

How has IRIDEX's stock been impacted by COVID-19?

IRIDEX's stock was trading at $1.97 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IRIX stock has increased by 20.3% and is now trading at $2.37.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of IRIDEX?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRIDEX in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for IRIDEX
.

When is IRIDEX's next earnings date?

IRIDEX is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for IRIDEX
.

How were IRIDEX's earnings last quarter?

IRIDEX Co. (NASDAQ:IRIX) announced its quarterly earnings results on Thursday, August, 6th. The medical equipment provider reported ($0.20) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.22) by $0.02. IRIDEX had a negative return on equity of 34.39% and a negative net margin of 20.65%.
View IRIDEX's earnings history
.

What price target have analysts set for IRIX?

2 brokers have issued twelve-month price objectives for IRIDEX's stock. Their forecasts range from $4.00 to $4.00. On average, they expect IRIDEX's stock price to reach $4.00 in the next year. This suggests a possible upside of 68.8% from the stock's current price.
View analysts' price targets for IRIDEX
.

Has IRIDEX been receiving favorable news coverage?

Headlines about IRIX stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IRIDEX earned a daily sentiment score of -3.9 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future.
View the latest news about IRIDEX
.

Are investors shorting IRIDEX?

IRIDEX saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 24,500 shares, an increase of 109.4% from the January 31st total of 11,700 shares. Based on an average daily volume of 67,500 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.2% of the company's shares are sold short.
View IRIDEX's Short Interest
.

Who are some of IRIDEX's key competitors?

What other stocks do shareholders of IRIDEX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IRIDEX investors own include Agile Therapeutics (AGRX), Gilead Sciences (GILD), SCYNEXIS (SCYX), AbbVie (ABBV), CTI BioPharma (CTIC), Riot Blockchain (RIOT), Sorrento Therapeutics (SRNE), Trevena (TRVN), Allena Pharmaceuticals (ALNA) and Capstone Turbine (CPST).

Who are IRIDEX's key executives?

IRIDEX's management team includes the following people:
  • Mr. William M. Moore, Chairman of Directors, Pres & CEO (Age 70)
  • Dr. George R. Marcellino, VP of Clinical Affairs (Age 70)
  • Mr. Romeo R. Dizon, VP of Fin.
  • Ms. Leigh Salvo, Head of Investor Relations
  • Mr. Timothy D. Buckley, VP of Marketing & North American Sales (Age 44)

What is IRIDEX's stock symbol?

IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."

How do I buy shares of IRIDEX?

Shares of IRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IRIDEX's stock price today?

One share of IRIX stock can currently be purchased for approximately $2.37.

How big of a company is IRIDEX?

IRIDEX has a market capitalization of $32.68 million and generates $43.45 million in revenue each year. The medical equipment provider earns $-8,810,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis.

What is IRIDEX's official website?

The official website for IRIDEX is www.iridex.com.

How can I contact IRIDEX?

IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The medical equipment provider can be reached via phone at 650-940-4700 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.